Enfusion Net Working Capital from 2010 to 2024

ENFN Stock  USD 9.94  0.08  0.80%   
Enfusion Net Working Capital yearly trend continues to be very stable with very little volatility. Net Working Capital is likely to grow to about 52.1 M this year. During the period from 2010 to 2024, Enfusion Net Working Capital quarterly data regression pattern had sample variance of 742.3 T and median of  8,095,000. View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
49.5 M
Current Value
52.1 M
Quarterly Volatility
27.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Enfusion financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enfusion's main balance sheet or income statement drivers, such as Tax Provision of 867 K, Net Interest Income of 1.7 M or Depreciation And Amortization of 5.3 M, as well as many indicators such as Price To Sales Ratio of 4.66, Dividend Yield of 0.0034 or PTB Ratio of 16.74. Enfusion financial statements analysis is a perfect complement when working with Enfusion Valuation or Volatility modules.
  
Check out the analysis of Enfusion Correlation against competitors.
To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.

Latest Enfusion's Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of Enfusion over the last few years. It is Enfusion's Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Enfusion's overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Slightly volatile
   Net Working Capital   
       Timeline  

Enfusion Net Working Capital Regression Statistics

Arithmetic Mean24,124,785
Geometric Mean14,830,134
Coefficient Of Variation112.93
Mean Deviation22,154,885
Median8,095,000
Standard Deviation27,245,243
Sample Variance742.3T
Range73.5M
R-Value0.73
Mean Square Error378.4T
R-Squared0.53
Significance0
Slope4,421,137
Total Sum of Squares10392.2T

Enfusion Net Working Capital History

202452.1 M
202349.5 M
202279.4 M
202181.6 M
202018.3 M

About Enfusion Financial Statements

Enfusion investors utilize fundamental indicators, such as Net Working Capital, to predict how Enfusion Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Working Capital49.5 M52.1 M

Pair Trading with Enfusion

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enfusion position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enfusion will appreciate offsetting losses from the drop in the long position's value.

Moving together with Enfusion Stock

  0.67U Unity Software Aggressive PushPairCorr
  0.72DJCO Daily Journal CorpPairCorr
  0.77AI C3 Ai Inc Earnings Call This WeekPairCorr
  0.81BL BlacklinePairCorr
  0.62DT Dynatrace Holdings LLCPairCorr

Moving against Enfusion Stock

  0.7VERB VERB TECHNOLOGY PANY Tech BoostPairCorr
  0.35VTEX VTEXPairCorr
  0.33EGAN eGainPairCorr
The ability to find closely correlated positions to Enfusion could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enfusion when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enfusion - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enfusion to buy it.
The correlation of Enfusion is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enfusion moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enfusion moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enfusion can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Enfusion offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enfusion's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enfusion Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enfusion Stock:
Check out the analysis of Enfusion Correlation against competitors.
To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.
You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enfusion. If investors know Enfusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enfusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.27)
Earnings Share
0.04
Revenue Per Share
2.155
Quarterly Revenue Growth
0.154
Return On Assets
0.0592
The market value of Enfusion is measured differently than its book value, which is the value of Enfusion that is recorded on the company's balance sheet. Investors also form their own opinion of Enfusion's value that differs from its market value or its book value, called intrinsic value, which is Enfusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enfusion's market value can be influenced by many factors that don't directly affect Enfusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enfusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Enfusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enfusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.